The Duty to Disclose Adverse Clinical Trial Results

Author： Liao S. Matthew   Sheehan Mark   Clarke Steve  

Publisher： Routledge Ltd

ISSN： 1536-0075

Source： American Journal of Bioethics, Vol.9, Iss.8, 2009-08, pp. : 24-32

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Duty to Disclose (Even More) Adverse Clinical Trial Results

By Hassoun Nicole  

American Journal of Bioethics, Vol. 9, Iss. 8, 2009-08 ,pp. : 33-34

Routledge Ltd

Access to resources Recommend Favorite

Enhancing Informed Consent in Clinical Trials and Exploring Resistances to Disclosing Adverse Clinical Trial Results

By Banja John   Dunlop Boadie  

American Journal of Bioethics, Vol. 9, Iss. 8, 2009-08 ,pp. : 39-41

Routledge Ltd

Access to resources Recommend Favorite

Disclosure of Adverse Clinical Trial Results—Should Legal Immunity Be Granted to Drug Companies?

By Vernillo Anthony  

American Journal of Bioethics, Vol. 9, Iss. 8, 2009-08 ,pp. : 45-47

Routledge Ltd

Access to resources Recommend Favorite

Improving Subject Recruitment By Maintaining Truly Informed Consent: A Practical Benefit of Disclosing Adverse Clinical Trial Results

By Shah Kavita   Batzer Frances  

American Journal of Bioethics, Vol. 9, Iss. 8, 2009-08 ,pp. : 36-37

Routledge Ltd

Access to resources Recommend Favorite

Should Researchers Disclose Results to Descendants?

By Rothstein Mark A.  

American Journal of Bioethics, Vol. 13, Iss. 10, 2013-10 ,pp. : 64-65

Routledge Ltd

Access to resources Recommend Favorite